623 results on '"Davey, Richard T"'
Search Results
52. CD4⁺ T Cell Responses to Interleukin-2 Administration in HIV-Infected Patients Are Directly Related to the Baseline Level of Immune Activation
53. Clinical Management of Ebola Virus Disease in the United States and Europe
54. A Proof-of-Concept Study of Short-Cycle Intermittent Antiretroviral Therapy with a Once-Daily Regimen of Didanosine, Lamivudine, and Efavirenz for the Treatment of Chronic HIV Infection
55. A Randomized, Double-Blinded, Placebo-Controlled Trial of Intermittent Administration of Interleukin-2 and Prednisone in Subjects Infected with Human Immunodeficiency Virus
56. Long-Cycle Structured Intermittent versus Continuous Highly Active Antiretroviral Therapy for the Treatment of Chronic Infection with Human Immunodeficiency Virus: Effects on Drug Toxicity and on Immunologic and Virologic Parameters
57. Pilot Study of the Effects of Intermittent Interleukin-2 on Human Immunodeficiency Virus (HIV)-Specific Immune Responses in Patients Treated during Recently Acquired HIV Infection
58. Cellular and Humoral Immunity to Ebola Zaire Glycoprotein and Viral Vector Proteins Following Immunization with Recombinant Vesicular Stomatitis Virus-Based Ebola Vaccine (rVSVΔG-EBOV-GP)
59. Human Immunodeficiency Virus Type 1 Quasi Species That Rebound after Discontinuation of Highly Active Antiretroviral Therapy Are Similar to the Viral Quasi Species Present before Initiation of Therapy
60. Effects of Intermittent Interleukin-2 Therapy on Plasma and Tissue Human Immunodeficiency Virus Levels and Quasi-Species Expression
61. A Randomized, Controlled, Phase II Trial Comparing Escalating Doses of Subcutaneous Interleukin-2 plus Antiretrovirals versus Antiretrovirals Alone in Human Immunodeficiency Virus-Infected Patients with CD4⁺ Cell Counts ⩾350/mm³
62. Interleukin-2 up-Regulates Expression of the Human Immunodeficiency Virus Fusion Coreceptor CCR5 by CD4⁺ Lymphocytes in vivo
63. Hepatitis G Virus and Human Immunodeficiency Virus Coinfection: Response to Interferon-α Therapy
64. Caring for Critically Ill Patients Infected With the Ebola Virus
65. Characteristics and Clinical Management of a Cluster of 3 Patients With Ebola Virus Disease, Including the First Domestically Acquired Cases in the United States
66. Challenges in Managing Patients who have Suspected or Confirmed Ebola Virus Infection at the National Institutes of Health
67. A Randomized Trial of High- versus Low-Dose Subcutaneous Interleukin-2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection
68. Plasma Viremia as a Sensitive Indicator of the Antiretroviral Activity of L-697,661
69. Posttraumatic Endophthalmitis: The Emerging Role of Bacillus cereus Infection
70. Laboratory Methods in the Diagnosis and Prognostic Staging of Infection with Human Immunodeficiency Virus Type 1
71. Fostamatinib for the Treatment of Hospitalized Adults With Coronavirus Disease 2019: A Randomized Trial
72. Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data
73. Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccine
74. Subcutaneous Administration of Interleukin-2 in Human Immunodeficiency Virus Type 1-Infected Persons
75. Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors
76. Inhibition of Immunoreactive Tumor Necrosis Factor-α by a Chimeric Antibody in Patients Infected with Human Immunodeficiency Virus Type 1
77. Combination Therapy with Didanosine and Interferon-α in Human Immunodeficiency Virus-Infected Patients: Results of a Phase I/II Trial
78. Preparing for Critical Care Services to Patients With Ebola
79. High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19
80. South American Hemorrhagic Fevers: A summary for clinicians
81. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies
82. Literature in brief
83. Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of >=300/mm(super 3): CPCRA 059
84. High-level HIV-1 viremia suppresses viral antigen-specific CD[4.sup.+] T cell proliferation
85. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic
86. Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients
87. Modeling Challenges of Ebola Virus–Host Dynamics during Infection and Treatment
88. Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy
89. Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials
90. Targeting pandemic influenza: a primer on influenza antivirals and drug resistance
91. Effect of interleukin-2 on the pool of latently infected, resting CD4(super.+) T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy
92. Interleukin-2 cycling causes transient increases in high-sensitivity C-reactive protein and D-dimer that are not associated with plasma HIV-RNA levels
93. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial
94. Limitations of Using a Single Postdose Midazolam Concentration to Predict CYP3A-Mediated Drug Interactions
95. Determination of the Underlying Cause of Death in Three Multicenter International HIV Clinical Trials
96. A Randomised Study of Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A
97. Reporting and Evaluation of HIV-Related Clinical Endpoints in Two Multicenter International Clinical Trials
98. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection
99. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy
100. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.